SYNH SEC Filings - Syneos Health Inc - Class A- Annual Report, Proxy Statement, Prospectus

Basic Stats

LEI	549300F1ZGKDS8P6GU13
CIK	1610950

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Syneos Health Inc - Class A

SEC Filings (Chronological Order)

This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.

October 10, 2023	15-12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36730 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its
October 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 SYNEOS HEALTH, IN UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission Fil
October 3, 2023	EX-99.1	Syneos Health Appoints Colin Shannon as Chief Executive Officer Industry Veteran Brings Decades of Experience Driving Growth at Global Biopharmaceutical Solutions Organizations Exhibit 99.1 News Release Syneos Health Appoints Colin Shannon as Chief Executive Officer Industry Veteran Brings Decades of Experience Driving Growth at Global Biopharmaceutical Solutions Organizations MORRISVILLE, N.C. – October 3, 2023 – Syneos Health, Inc. (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organization, today announced that Colin Shannon
September 28, 2023	S-8 POS	As filed with the Securities and Exchange Commission on September 28, 2023 As filed with the Securities and Exchange Commission on September 28, 2023 Registration No.
September 28, 2023	S-8 POS	As filed with the Securities and Exchange Commission on September 28, 2023 As filed with the Securities and Exchange Commission on September 28, 2023 Registration No.
September 28, 2023	EX-3.2	FIFTH AMENDED AND RESTATED BY-LAWS SYNEOS HEALTH, INC. A Delaware Corporation (Adopted as of September 28, 2023) ARTICLE I EX-3.2 Exhibit 3.2 FIFTH AMENDED AND RESTATED BY-LAWS OF SYNEOS HEALTH, INC. A Delaware Corporation (Adopted as of September 28, 2023) ARTICLE I OFFICES Section 1. Registered Office. The registered office of Syneos Health, Inc. (the “Corporation”) in the State of Delaware shall be located at 1209 Orange Street, in the City of Wilmington, County of New Castle, Delaware 19801. The name of the Corpor
September 28, 2023	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2023 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission
September 28, 2023	EX-3.1	CERTIFICATE OF INCORPORATION OF INC RESEARCH HOLDINGS, INC. ARTICLE I Exhibit 3.1 CERTIFICATE OF INCORPORATION OF INC RESEARCH HOLDINGS, INC. ARTICLE I 1.1 Name. The name of the Corporation is: INC Research Holdings, Inc. ARTICLE II 2.1 Address. The address of the Corporation’s registered office in the State of Delaware is c/o Corporation Service Company, 251 Little Falls Drive, in the City of Wilmington, County of New Castle 19808. The name of its registered agent
September 28, 2023	S-8 POS	As filed with the Securities and Exchange Commission on September 28, 2023 As filed with the Securities and Exchange Commission on September 28, 2023 Registration No.
September 28, 2023	S-8 POS	As filed with the Securities and Exchange Commission on September 28, 2023 As filed with the Securities and Exchange Commission on September 28, 2023 Registration No.
September 6, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission F
September 6, 2023	EX-99.1	Health, Inc. and Star Parent, Inc. Announce Proposed $1.70 Billion Offering of Senior Secured Notes Exhibit 99.1 Syneos Health, Inc. and Star Parent, Inc. Announce Proposed $1.70 Billion Offering of Senior Secured Notes Morrisville, N.C. – September 6, 2023 – Star Parent, Inc. (the “Issuer” or the “Company”) and Syneos Health, Inc. (“Syneos Health”), announced today that, subject to market conditions and other factors, the Issuer intends to offer $1,700,000,000 aggregate principal amount of Seni
August 9, 2023	EX-10.2	June 13, 2023 Exhibit 10.2 June 13, 2023 VIA EMAIL Dear Ben, This is a formal confirmation of your role as EVP, Corporate Development and Strategy of Syneos Health, Inc. (the “Company”) reporting to Michelle Keefe, effective July 1, 2023. Your compensation terms will be as follows: Base Salary: Your current salary is $400,000. Annual Target bonus: Your target bonus for 2023 is $200,000. Executive Severance Prog
August 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36730 SYNEOS H
August 3, 2023	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission File
July 26, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
June 27, 2023	EX-FILING FEES	CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Syneos Health, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Proposed Maximum Aggregate Value of Transaction Fee Rate Amount of Filing Fee Fees to EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Syneos Health, Inc.
June 27, 2023	DEFM14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive Proxy Statement [ ] Definitive Additional Materials [ ] Soliciting Material Pursuant to §240.
June 27, 2023	PRER14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
June 15, 2023	EX-FILING FEES	CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Syneos Health, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Proposed Maximum Aggregate Value of Transaction Fee Rate Amount of Filing Fee Fees to EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Syneos Health, Inc.
June 15, 2023	PREM14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 PREM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive Proxy Statement [ ] Definitive Additional Materials [ ] Soliciting Material Pursuant to §240.
June 9, 2023	SC 13G/A	SYNH / Syneos Health Inc - Class A / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Syneos Health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 87166B102 (CUSIP Number) May 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul
May 15, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement.
May 10, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement.
May 10, 2023	EX-99.1	Syneos Health Reports First Quarter 2023 Results EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Syneos Health Reports First Quarter 2023 Results • Revenue for the first quarter of $1,356.8 million increased 1.5% on a reported basis and increased 2.4% on a constant currency basis year-over-year. • Clinical Solutions net new business awards and book-to-bill ratios: • Including reimbursable out-of-pocket expenses, $713.6 million for the first quarter,
May 10, 2023	EX-10	Form of Global Restricted Stock Unit Award Agreement under Syneos Health, Inc. 2018 Equity Incentive Plan (Non-U.S. Participants) (2023). Exhibit 10.5.2 SYNEOS HEALTH, INC. 2018 Equity Incentive Plan Global Restricted Stock Unit Award Agreement This Global Restricted Stock Unit Award Agreement (the “Restricted Stock Unit Agreement”), including any special terms and conditions for the Participant’s country set forth in the Appendix B attached hereto (the Global Restricted Stock Unit Agreement, the Appendix B and all other appendices
May 10, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 SYNEOS HEALTH, INC. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commissio
May 10, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement.
May 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 SYNEOS HEALTH, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission File N
May 10, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 SYNEOS HEALTH, INC. DEFA14A 1 d477753ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdictio
May 10, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement.
May 10, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement.
May 10, 2023	EX-2.1	Agreement and Plan of Merger, dated as of May 10, 2023, by and among Star Parent, Inc., Star Merger Sub, Inc. and Syneos Health, Inc. (filed herewith)* EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER BY AND AMONG STAR PARENT, INC., STAR MERGER SUB, INC. AND SYNEOS HEALTH, INC. MAY 10, 2023 TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS 2 Section 1.01 Definitions 2 Section 1.02 Definitional and Interpretative Provisions 19 ARTICLE II. THE TRANSACTION 20 Section 2.01 The Closing 20 Section 2.02 The Merger 21 ARTICLE III. CONVERSION OF SECURITIES 22
May 10, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement.
May 10, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEFA14A 1 d506381ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy
May 10, 2023	EX-10	Form of Global Restricted Stock Unit Award Agreement under Syneos Health, Inc. 2018 Equity Incentive Plan (U.S. Participants) (2023). Exhibit 10.5.1 SYNEOS HEALTH, INC. 2018 Equity Incentive Plan Global Restricted Stock Unit Award Agreement This Global Restricted Stock Unit Award Agreement (the “Restricted Stock Unit Agreement”), including any special terms and conditions for the Participant’s country set forth in the Appendix C attached hereto (the Global Restricted Stock Unit Agreement, the Appendix C and all other appendices
May 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT P UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36730 SYNEOS
May 10, 2023	EX-4	Sixth Supplemental Indenture, dated as of February 24, 2023, among the Guaranteeing Subsidiaries, the Company, the other Guarantors, and Wells Fargo Bank, National Association, as trustee. Exhibit 4.1 SIXTH SUPPLEMENTAL INDENTURE Sixth Supplemental Indenture (this “Supplemental Indenture”), dated as of February 24, 2023, among the undersigned Subsidiary (the “Guaranteeing Subsidiary”), a subsidiary of Syneos Health, Inc. (or its permitted successor), a Delaware corporation (the “Company”), the Company, the other Guarantors (as defined in the Indenture referred to herein) and Compute
May 10, 2023	EX-99.1	Syneos Health to be Acquired by a Private Investment Consortium for Approximately $7.1 Billion Shareholders to Receive $43.00 Per Share in Cash Represents 24% Premium to Unaffected Stock Price EX-99.1 Exhibit 99.1 Syneos Health Transaction Press Release Syneos Health to be Acquired by a Private Investment Consortium for Approximately $7.1 Billion Shareholders to Receive $43.00 Per Share in Cash Represents 24% Premium to Unaffected Stock Price MORRISVILLE, N.C., May 10, 2023 – Syneos Health, Inc. (Nasdaq: SYNH) (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceuti
May 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 SYNEOS HEALTH, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission File N
May 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 SYNEOS HEALTH, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission File N
May 10, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 SYNEOS HEALTH, INC. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commissio
May 10, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement.
May 2, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2023 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission File
May 2, 2023	EX-10.1	Offer Letter for Michael Bonello, dated April 7, 2023. EX-10.1 Exhibit 10.1 April 7, 2023 Michael Bonello [*] [*] Dear Michael, As you know we’re on a journey to create the industry’s leading biopharmaceutical solutions organization. To that end, on behalf of the Board and all of us who’ve been engaged in the conversation, I’m delighted to offer you the position of Chief Financial Officer reporting to Michelle Keefe, CEO. We’re confident that your
May 1, 2023	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-
March 30, 2023	EX-10.1	Letter from Syneos Health, Inc. to Stanford Rudnick, dated March 29, 2023 Exhibit 10.1 March 29, 2023 VIA EMAIL Dear Ben, This is a formal confirmation of your role as EVP, Business Finance and Interim CFO of Syneos Health, Inc. (the “Company”) reporting to Michelle Keefe. Your compensation terms will be as follows: Base Salary: Your current salary is $400,000. Effective April 1, 2023, you will also receive an interim stipend equal to $17,000 per month while you serve a
March 30, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 SYNEOS HEALTH, INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission File
February 16, 2023	EX-99	Syneos Health Reports Fourth Quarter and Full Year 2022 Results Exhibit 99.1 FOR IMMEDIATE RELEASE Syneos Health Reports Fourth Quarter and Full Year 2022 Results • Revenue for the fourth quarter of $1,359.9 million decreased 1.0% on a reported basis and increased 1.7% on a constant currency basis year-over-year. • Clinical Solutions net new business awards and book-to-bill ratios: o Including reimbursable out-of-pocket expenses, $470.1 million for the fourth
February 16, 2023	EX-21	List of Subsidiaries of the Registrant. Exhibit 21.1 List of Subsidiaries of Syneos Health, Inc. Entity Name Jurisdiction Addison Whitney LLC North Carolina Allidura Communications LLC Delaware BioSector 2 LLC New York Boco Digital Media, LLC Pennsylvania Cadent Medical Communications, LLC Ohio Caerus Marketing Group, LLC California Chamberlain Communications Group LLC Delaware Chandler Chicco Agency, L.L.C. New York Genicos, LLC Ohio G
February 16, 2023	EX-4	Description of Capital Stock. Exhibit 4.9 DESCRIPTION OF CAPITAL STOCK The following description of the capital stock of Syneos Health, Inc. (the “Company,” “we,” “us,” and “our”) and certain provisions of our Certificate of Incorporation, as may be amended from time to time (the “Certificate”) and our Amended and Restated Bylaws, as may be amended from time to time (the “Bylaws”) is a summary and is qualified in its entirety
February 16, 2023	EX-10	Form of Global Performance Restricted Stock Unit Award Agreement under Syneos Health, Inc. 2018 Equity Incentive Plan (Non-U.S. Participants) (2022). Exhibit 10.11.15 SYNEOS HEALTH, INC. 2018 Equity Incentive Plan Global Performance Restricted Stock Unit Award Agreement This Global Performance Restricted Stock Unit Award Agreement including any special terms and conditions for the Participant’s country set forth in Appendix B, attached hereto (the Global Performance Restricted Stock Unit Agreement, the Appendix B and all other appendices attach
February 16, 2023	EX-10	Form of Global Performance Restricted Stock Unit Award Agreement under Syneos Health, Inc. 2018 Equity Incentive Plan (U.S. Participants) (2022). Exhibit 10.11.14 SYNEOS HEALTH, INC. 2018 Equity Incentive Plan Global Performance Restricted Stock Unit Award Agreement This Global Performance Restricted Stock Unit Award Agreement including any special terms and conditions for the Participant’s country set forth in Appendix B, attached hereto (the Global Performance Restricted Stock Unit Agreement, the Appendix B and all other appendices attach
February 16, 2023	EX-10	Form of Global Restricted Stock Unit Award Agreement under Syneos Health, Inc. 2018 Equity Incentive Plan (Non-U.S. Participants) (2022). Exhibit 10.11.12 SYNEOS HEALTH, INC. 2018 Equity Incentive Plan Global Restricted Stock Unit Award Agreement This Global Restricted Stock Unit Award Agreement (the “Restricted Stock Unit Agreement”), including any special terms and conditions for the Participant’s country set forth in the Appendix B attached hereto (the Global Restricted Stock Unit Agreement, the Appendix B and all other appendice
February 16, 2023	EX-10	Form of Global Restricted Stock Unit Award Agreement under Syneos Health, Inc. 2018 Equity Incentive Plan (U.S. Participants) (2022) Exhibit 10.11.13 SYNEOS HEALTH, INC. 2018 Equity Incentive Plan Global Restricted Stock Unit Award Agreement This Global Restricted Stock Unit Award Agreement (the “Restricted Stock Unit Agreement”), including any special terms and conditions for the Participant’s country set forth in the Appendix C attached hereto (the Global Restricted Stock Unit Agreement, the Appendix C and all other appendice
February 16, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 SYNEOS HEALTH, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission F
February 16, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36730 SYNEOS HEALTH,
February 16, 2023	EX-10	Form of Global Restricted Stock Unit Award Agreement under Syneos Health, Inc. 2018 Equity Incentive Plan (U.S. Participants) (2023) Exhibit 10.11.16 SYNEOS HEALTH, INC. 2018 Equity Incentive Plan Global Restricted Stock Unit Award Agreement This Global Restricted Stock Unit Award Agreement (the “Restricted Stock Unit Agreement”), including any special terms and conditions for the Participant’s country set forth in the Appendix C attached hereto (the Global Restricted Stock Unit Agreement, the Appendix C and all other appendice
February 16, 2023	EX-10	Form of Global Performance Restricted Stock Unit Award Agreement under Syneos Health, Inc. 2018 Equity Incentive Plan (U.S. Participants) (2023). Exhibit 10.11.17 SYNEOS HEALTH, INC. 2018 Equity Incentive Plan Global Performance Restricted Stock Unit Award Agreement This Global Performance Restricted Stock Unit Award Agreement including any special terms and conditions for the Participant’s country set forth in Appendix B, attached hereto (the Global Performance Restricted Stock Unit Agreement, the Appendix B and all other appendices attach
February 16, 2023	EX-10	Executive Service Agreement, by and between Syneos Health UK Limited and Christian Tucat, dated February 14, 2023. Exhibit 10.7 EXECUTIVE SERVICE AGREEMENT between SYNEOS HEALTH UK LIMITED and CHRISTIAN TUCAT Company: Syneos Health UK Limited whose registered office is at 1 Pinehurst Road, Farnborough Business Park, Farnborough, Hampshire GU14 7BF (the Company); and Employee: Christian Tucat of [***]. This Contract supersedes any earlier written or oral arrangement between you and the Company. There are no Col
February 6, 2023	SC 13G/A	SYNH / Syneos Health Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Syneos Health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 87166B102 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to
January 11, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2023 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission Fi
January 11, 2023	EX-99.1	Forward Looking Statement Except for historical information, all of the statements, expectations, and assumptions contained in this presentation are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 41st Annual J.P. Morgan Healthcare Conference Syneos Health January 11, 2023 Exhibit 99.1 Forward Looking Statement Except for historical information, all of the statements, expectations, and assumptions contained in this presentation are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the
January 10, 2023	SC 13G/A	SYNH / Syneos Health Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Syneos Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 87166B102 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒
January 9, 2023	EX-10.2	Consulting Agreement between Jason Meggs and Syneos Health, Inc., dated January 5, 2023. EX-10.2 3 d426909dex102.htm EX-10.2 Exhibit 10.2 CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is entered into by and between Jason Meggs (“Consultant”) and Syneos Health, Inc., a Delaware corporation (the “Company”), is dated January 5, 2023 and is effective as of July 1, 2023. 1. Separation of Employment. (a) Effective as of July 1, 2023 (the “Separation Date), Consultant’s em
January 9, 2023	EX-10.1	Separation Agreement and General Release of Claims between Jason Meggs and Syneos Health, Inc., dated January 5, 2023. EX-10.1 2 d426909dex101.htm EX-10.1 Exhibit 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS This Separation Agreement and General Release of Claims (“Agreement”) is made and entered into by and between Jason Meggs (“Employee” or “You” or “Your”) and Syneos Health, Inc. (“Syneos Health” or the “Company”). This Agreement supersedes all prior employment agreements or arrangements of any kind
January 9, 2023	EX-99.1	Syneos Health Announces Chief Financial Officer Transition Reaffirms Full-Year 2022 Revenue Guidance Exhibit 99.1 FOR IMMEDIATE RELEASE Syneos Health Announces Chief Financial Officer Transition Reaffirms Full-Year 2022 Revenue Guidance MORRISVILLE, N.C., January 9, 2023 - Syneos Health® (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that, effective March 31, 2023, Jason Meggs will transition from his role as Chief Financial Officer to pursue o
January 9, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2023 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission Fil
December 23, 2022	EX-3.1	Fourth Amended and Restated Bylaws of Syneos Health, Inc. synh-ex3119.htm Exhibit 3.1 FOURTH AMENDED AND RESTATED BYLAWS OF SYNEOS HEALTH, INC. (a Delaware corporation) Effective December 23, 2022 ARTICLE I STOCKHOLDERS Section 1.01. Annual Meetings. The annual meeting of the stockholders of Syneos Health, Inc. (the ?Corporation?) for the election of directors and for the transaction of such other business as properly may come before such meeting shall b
December 23, 2022	EX-3.2	Fourth Amended and Restated Bylaws of Syneos Health, Inc., marked to show amendments. EX-3.2 3 synh-ex3284.htm EX-3.2 Exhibit 3.2 THIRDFOURTH AMENDED AND RESTATED BYLAWS OF SYNEOS HEALTH, INC. (a Delaware corporation) Effective May 25December 23, 2022 ARTICLE I STOCKHOLDERS Section 1.01. Annual Meetings. The annual meeting of the stockholders of Syneos Health, Inc. (the “Corporation”) for the election of directors and for the transaction of such other business as properly may come
December 23, 2022	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits synh-8k20221223.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2022 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorpor
November 7, 2022	EX-10.1	Amended & Restated Credit Agreement, dated November 4, 2022, among Syneos Health, Inc., Syneos Health US, Inc., the lenders party thereto, JPMorgan Chase Bank N.A. (“JPMorgan”), as Administrative Agent and Collateral Agent, and each of the other parties thereto. EX-10.1 2 synh-ex1016.htm EX-10.1 Exhibit 10.1 EXECUTION VERSION AMENDED AND RESTATED CREDIT AGREEMENT Dated as of November 4, 2022 among SYNEOS HEALTH, INC., as the Administrative Borrower, the other BORROWERS party hereto, THE FINANCIAL INSTITUTIONS PARTY HERETO, as Lenders, JPMORGAN CHASE BANK, N.A., as Administrative Agent, JPMORGAN CHASE BANK, N.A., BOFA SECURITIES, INC., PNC CAPITAL MARKETS
November 7, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2022 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission Fi
November 4, 2022	EX-10.3	Twelfth Amendment to the Receivables Financing Agreement, dated as of October 3, 2022, by and among Syneos Health Receivables LLC, as borrower, Syneos Health, LLC, as initial servicer, Regions Bank, as lender, and PNC Bank, National Association, as administrative agent and as a lender. EX-10.3 5 synh-ex103.htm EX-10.3 Exhibit 10.3 EXECUTION VERSION TWELFTH AMENDMENT TO THE RECEIVABLES FINANCING AGREEMENT This TWELFTH AMENDMENT TO THE RECEIVABLES FINANCING AGREEMENT (this “Amendment”), dated as of October 3, 2022, is entered into by and among the following parties: (i) SYNEOS HEALTH RECEIVABLES LLC, as Borrower; (ii) SYNEOS HEALTH, LLC (f/k/a INC RESEARCH, LLC), as initial Servic
November 4, 2022	EX-99.1	Syneos Health Reports Third Quarter 2022 Results Exhibit 99.1 FOR IMMEDIATE RELEASE Syneos Health Reports Third Quarter 2022 Results • Revenue for the third quarter of $1,336.2 million decreased 0.9% on a reported basis and increased 2.2% on a constant currency basis year-over-year. • Clinical Solutions net new business awards and book-to-bill ratios: o Including reimbursable out-of-pocket expenses, $182.2 million for the third quarter, a year-o
November 4, 2022	EX-10.2	Supplemental Release between Syneos Health, Inc. and Paul Colvin. Exhibit 10.2 Exhibit A SUPPLEMENTAL RELEASE AGREEMENT By signing this Supplemental Release Agreement where indicated below, I acknowledge and agree that I am hereby extending, through and including the date I sign below, the application of all of my representations, obligations, acknowledgements, and other provisions reflected in the Separation Agreement and General Release of Claims, dated August
November 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36730 SYN
November 4, 2022	EX-10.1	Separation Agreement and General Release of Claims between Syneos Health, Inc. and Paul Colvin. Exhibit 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS This Separation Agreement and General Release of Claims (“Agreement”) is made and entered into by Paul Colvin (“Employee” or “You” or “Your”) and Syneos Health, Inc., any parent, subsidiary, affiliate, successor, predecessor or otherwise related companies, and the past, present, and future employees, agents, officers, attorneys, direc
November 4, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2022 SYNEOS HEALTH, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2022 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission Fi
November 4, 2022	EX-4.1	Fifth Supplemental Indenture, dated as of October 3, 2022, among the Guaranteeing Subsidiaries, the Company, the other Guarantors, and Wells Fargo Bank, National Association, as trustee. Exhibit 4.1 FIFTH SUPPLEMENTAL INDENTURE Fifth Supplemental Indenture (this “Supplemental Indenture”), dated as of October 3, 2022, among each undersigned Subsidiary (the “Guaranteeing Subsidiary”), each a subsidiary of Syneos Health, Inc. (or its permitted successor), a Delaware corporation (the “Company”), the Company, the other Guarantors (as defined in the Indenture referred to herein) and Wel
October 14, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2022 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission Fi
September 13, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2022 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission
September 13, 2022	EX-99.1	Except for historical information, all of the statements, expectations, and assumptions contained in this presentation are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including the futur 2022 Annual Baird Global Healthcare Conference Michelle Keefe, CEO Jason Meggs, CFO September 13, 2022 Exhibit 99.
August 2, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36730 SYNEOS H
August 2, 2022	EX-10.5	Deed of Amendment related to the Consulting Agreement and Settlement Agreement between Syneos Health UK Limited, Syneos Health, Inc. and Alistair Macdonald, dated June 29, 2022. Exhibit 10.5 29 June 2022 29 June 2022 SYNEOS HEALTH UK LIMITED (as Syneos) and SYNEOS HEALTH, INC. (as Syneos Health, Inc.) and ALISTAIR MACDONALD (as Executive) (as Executive) 1 EU-DOCS\38838200.1 DEED OF AMENDMENT related to the CONSULTING AGREEMENT AND SETTLEMENT AGREEMENT 2 EU-DOCS\38838200.1 THIS DEED OF AMENDMENT (this ?Deed?) is entered into on 29 June 2022 BETWEEN: (1) SYNEOS HEALTH UK LI
August 2, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission File
August 2, 2022	EX-10.6	Form of Global Restricted Stock Unit Award Agreement under Syneos Health, Inc. 2018 Equity Incentive Plan (U.S. Participants) (2022). Exhibit 10.6 SYNEOS HEALTH, INC. 2018 Equity Incentive Plan Global Restricted Stock Unit Award Agreement This Global Restricted Stock Unit Award Agreement (the ?Restricted Stock Unit Agreement?), including any special terms and conditions for the Participant?s country set forth in the Appendix C attached hereto (the Global Restricted Stock Unit Agreement, the Appendix C and all other appendices at
August 2, 2022	EX-10.7	Form of Indemnification and Advancement Agreement. EX-10.7 5 synh-ex107.htm EX-10.7 Exhibit 10.7 INDEMNIFICATION And Advancement AGREEMENT This Indemnification and Advancement Agreement (“Agreement”) is made as of , 20 by and between Syneos Health, Inc., a Delaware corporation (the “Company”), and , [a member of the Board of Directors/an officer/an employee/an agent/a fiduciary] of the Company (“Indemnitee”). This Agreement supersedes and replaces
August 2, 2022	EX-10.4	Agreement between Syneos Health UK Limited and Alistair Macdonald, dated April 29, 2022 and July 8, 2022. Exhibit 10.4 WITHOUT PREJUDICE AND SUBJECT TO CONTRACT THIS DEED is made on April 29, 2022 and again on 08 July 2022 BETWEEN (1) SYNEOS HEALTH UK LIMITED, a company registered in England with registered number 04428083 and having its registered office at Farnborough Business Park, 1 Pinehurst Road, Farnborough, Hampshire, England, GU14 7BF (the ?Company?); and (2) ALISTAIR MACDONALD, residing at W
August 2, 2022	EX-99.1	Syneos Health Reports Second Quarter 2022 Results Exhibit 99.1 FOR IMMEDIATE RELEASE Syneos Health Reports Second Quarter 2022 Results ? Revenue for the second quarter of $1,360.7 million increased 6.1% on a reported basis and 8.3% on a constant currency basis year-over-year. ? Clinical Solutions net new business awards and book-to-bill ratios: o Including reimbursable out-of-pocket expenses, $947.4 million for the second quarter, a year-over-yea
June 1, 2022	EX-3.1	Certificate of Amendment to the Certificate of Incorporation of Syneos Health, Inc. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF SYNEOS HEALTH, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware The undersigned, for purposes of amending the Certificate of Incorporation, as amended (the ?Certificate of Incorporation?), of Syneos Health, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of
June 1, 2022	EX-3.3	Third Amended and Restated Bylaws of Syneos Health, Inc., marked to show amendments. Exhibit 3.3 SECOND THIRD AMENDED AND RESTATED BYLAWS OF SYNEOS HEALTH, INC. (a Delaware corporation) Effective January 4 May 25, 2018 2022 ARTICLE I STOCKHOLDERS Section 1.01. Annual Meetings. The annual meeting of the stockholders of Syneos Health, Inc. (the ?Corporation?) for the election of directors and for the transaction of such other business as properly may come before such meeting shall b
June 1, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2022 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission File N
June 1, 2022	EX-3.2	Third Amended and Restated Bylaws of Syneos Health, Inc. Exhibit 3.2 THIRD AMENDED AND RESTATED BYLAWS OF SYNEOS HEALTH, INC. (a Delaware corporation) Effective May 25, 2022 ARTICLE I STOCKHOLDERS Section 1.01. Annual Meetings. The annual meeting of the stockholders of Syneos Health, Inc. (the ?Corporation?) for the election of directors and for the transaction of such other business as properly may come before such meeting shall be held at such place,
April 29, 2022	EX-10.2	Letter Agreement between Syneos Health, Inc. and Michael Brooks, dated April 29, 2022. Exhibit 10.2 April 29, 2022 Michael Brooks 1030 Sync Street Morrisville, North Carolina 27560 Dear Michael, On behalf of Syneos Health (the ?Company?), the Board of Directors (the ?Board?) and all of us who?ve been engaged in the conversation, I?m delighted to offer you the position of Chief Operating Officer (?COO?) reporting to the Company?s Chief Executive Officer. We?re confident that your con
April 29, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2022 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission File
April 29, 2022	EX-99.1	Syneos Health Reports First Quarter 2022 Results Exhibit 99.1 FOR IMMEDIATE RELEASE Syneos Health Reports First Quarter 2022 Results Highlights ? Revenue for the first quarter of $1,336.3 million increased 10.5% on a reported basis and 11.7% on a constant currency basis year-over-year. ? Clinical Solutions net new business awards and book-to-bill ratios: ? Including reimbursable out-of-pocket expenses, $1,241.9 million for the first quarter, yea
April 29, 2022	EX-10.1	Letter Agreement between Syneos Health, Inc. and Michelle Keefe, dated April 29, 2022. Exhibit 10.1 April 29, 2022 Michelle Keefe 1030 Sync Street Morrisville, North Carolina 27560 Dear Michelle, On behalf of Syneos Health (the ?Company?), the Board of Directors (the ?Board?) and all of us who?ve been engaged in the conversation, I?m delighted to offer you the position of Chief Executive Officer (?CEO?) with duties, responsibilities, and authorities commensurate with such position,
April 29, 2022	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2022 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission File
April 29, 2022	EX-4.1	Fourth Supplemental Indenture, dated as of April 5, 2022, among the Guaranteeing Subsidiaries, the Company, the other Guarantors, and Wells Fargo Bank, National Association, as trustee. Exhibit 4.1 FOURTH SUPPLEMENTAL INDENTURE Fourth Supplemental Indenture (this ?Supplemental Indenture?), dated as of April 5, 2022, among each undersigned Subsidiary (the ?Guaranteeing Subsidiaries?), each a subsidiary of Syneos Health, Inc. (or its permitted successor), a Delaware corporation (the ?Company?), the Company, the other Guarantors (as defined in the Indenture referred to herein) and W
April 29, 2022	EX-10.3	Agreement between Syneos Health UK Limited and Alistair Macdonald, dated April 29, 2022. Exhibit 10.3 WITHOUT PREJUDICE AND SUBJECT TO CONTRACT THIS DEED is made on April 29, 2022 and again on BETWEEN (1) SYNEOS HEALTH UK LIMITED, a company registered in England with registered number 04428083 and having its registered office at Farnborough Business Park, 1 Pinehurst Road, Farnborough, Hampshire, England, GU14 7BF (the ?Company?); and (2) ALISTAIR MACDONALD, residing at Wilton House,
April 29, 2022	EX-10.4	Consulting Agreement between Syneos Health, Inc. and Alistair Macdonald, dated April 29, 2022. Exhibit 10.4 THIS AGREEMENT is made on April 29, 2022 BETWEEN (1) SYNEOS HEALTH, INC., a Delaware company (the ?Company?); and (2) ALISTAIR MACDONALD, residing at Wilton House, 13 Sunning Avenue, Sunningdale, Berkshire, SL5 9PN (the ?Consultant?). BACKGROUND The Company wishes to benefit from the skills and abilities of the Consultant and the Consultant is an independent contractor who has agreed
April 29, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36730 SYNEOS
April 12, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEFA14A 1 synh-defa14a20220525.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary P
April 12, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement.
April 1, 2022	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement.
February 17, 2022	EX-4.6	Third Supplemental Indenture, dated as of November 19, 2021, among the Company, the subsidiary guarantors named on the signature pages thereto, the other guarantors, and Wells Fargo Bank, National Association, as trustee. Exhibit 4.6 THIRD SUPPLEMENTAL INDENTURE Third Supplemental Indenture (this ?Supplemental Indenture?), dated as of November 19, 2021, among each undersigned Subsidiary (the ?Guaranteeing Subsidiaries?), each a subsidiary of Syneos Health, Inc. (or its permitted successor), a Delaware corporation (the ?Company?), the Company, the other Guarantors (as defined in the Indenture referred to herein) and
February 17, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36730 SYNEOS HEALTH,
February 17, 2022	EX-10.12.7	Amendment No. 6 to the Credit Agreement, dated as of December 17, 2021, among the Company, JPMorgan Chase Bank N.A., as administrative agent and collateral agent for the Lenders, and the other parties thereto. Exhibit 10.12.7 EXECUTION VERSION AMENDMENT NO. 6 AMENDMENT NO. 6, dated as of December 17, 2021 (this ?Amendment No. 6? or this ?Agreement?), among SYNEOS HEALTH, INC. (f/k/a INC Research Holdings, Inc.), a Delaware corporation (the ?Administrative Borrower?), JPMORGAN CHASE BANK, N.A., as administrative agent and collateral agent for the Lenders (in such capacities, the ?Agent?), and the other p
February 17, 2022	EX-10.7	Letter Agreement, dated September 21, 2020, by and between Syneos Health, Inc. and Michael Brooks. Exhibit 10.7 September 21, 2020 Michael Brooks [redacted] Dear Michael, As you know, we?re on a journey to create the industry?s leading biopharmaceutical solutions organization. To that end, on behalf of the Board and all of us who?ve been engaged in the conversation, I?m delighted to offer you the position of Chief Development Officer reporting to Alistair Macdonald, CEO. We?re confident that yo
February 17, 2022	EX-10.11.8	Form of Global Performance Restricted Stock Unit Award Agreement under Syneos Health, Inc. 2018 Equity Incentive Plan (Non-U.S. Participants) (2022). Exhibit 10.11.8 SYNEOS HEALTH, INC. 2018 Equity Incentive Plan Global Performance Restricted Stock Unit Award Agreement This Global Performance Restricted Stock Unit Award Agreement including any special terms and conditions for the Participant?s country set forth in Appendix B, attached hereto (the Global Performance Restricted Stock Unit Agreement, the Appendix B and all other appendices attache
February 17, 2022	EX-21.1	List of Subsidiaries of the Registrant. Exhibit 21.1 List of Subsidiaries of Syneos Health, Inc. Entity Name Jurisdiction Addison Whitney LLC North Carolina Allidura Communications LLC Delaware AmberCRO Armenia Limited Armenia BioSector 2 LLC New York Cadent Medical Communications, LLC Ohio Caerus Marketing Group, LLC California Chamberlain Communications Group LLC Delaware Chandler Chicco Agency, L.L.C. New York Gerbig Snell/Weisheimer
February 17, 2022	EX-10.11.7	Form of Global Performance Restricted Stock Unit Award Agreement under Syneos Health, Inc. 2018 Equity Incentive Plan (U.S. Participants) (2022). Exhibit 10.11.7 SYNEOS HEALTH, INC. 2018 Equity Incentive Plan Global Performance Restricted Stock Unit Award Agreement This Global Performance Restricted Stock Unit Award Agreement including any special terms and conditions for the Participant?s country set forth in Appendix B, attached hereto (the Global Performance Restricted Stock Unit Agreement, the Appendix B and all other appendices attache
February 17, 2022	EX-10.11.10	Form of Global Restricted Stock Unit Award Agreement under Syneos Health, Inc. 2018 Equity Incentive Plan (Non-U.S. Participants) (2022). Exhibit 10.11.10 SYNEOS HEALTH, INC. 2018 Equity Incentive Plan Global Restricted Stock Unit Award Agreement This Global Restricted Stock Unit Award Agreement (the ?Restricted Stock Unit Agreement?), including any special terms and conditions for the Participant?s country set forth in the Appendix B attached hereto (the Global Restricted Stock Unit Agreement, the Appendix B and all other appendice
February 17, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2022 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission F
February 17, 2022	EX-99.1	Syneos Health Reports Fourth Quarter and Full Year 2021 Results Exhibit 99.1 FOR IMMEDIATE RELEASE Syneos Health Reports Fourth Quarter and Full Year 2021 Results Highlights ? Fourth quarter revenue of $1,373.4 million increased 20.5% year-over-year. ? Clinical Solutions net new business awards and book-to-bill ratios: ? Including reimbursable out-of-pocket expenses, $357.1 million for the fourth quarter, a year-over-year decline of 72.9% and a book-to-bill ra
February 17, 2022	EX-10.11.9	Form of Global Restricted Stock Unit Award Agreement under Syneos Health, Inc. 2018 Equity Incentive Plan (U.S. Participants) (2022). Exhibit 10.11.9 SYNEOS HEALTH, INC. 2018 Equity Incentive Plan Global Restricted Stock Unit Award Agreement This Global Restricted Stock Unit Award Agreement (the ?Restricted Stock Unit Agreement?), including any special terms and conditions for the Participant?s country set forth in the Appendix C attached hereto (the Global Restricted Stock Unit Agreement, the Appendix C and all other appendices
February 10, 2022	SC 13G/A	SYNH / Syneos Health Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Syneos Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 87166B102 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??
February 4, 2022	SC 13G/A	SYNH / Syneos Health Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Syneos Health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 87166B102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc
January 18, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2022 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission Fi
November 16, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission F
November 15, 2021	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission F
November 3, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36730 SYN
November 3, 2021	EX-10.1	Eleventh Amendment to the Receivables Financing Agreement, dated as of October 13, 2021, by and among Syneos Health Receivables LLC, as borrower, Syneos Health, LLC, as initial servicer, Regions Bank, as a lender, and PNC Bank, National Association, as administrative agent and as a lender. Exhibit 10.1 EXECUTION VERSION ELEVENTH AMENDMENT TO THE RECEIVABLES FINANCING AGREEMENT This ELEVENTH AMENDMENT TO THE RECEIVABLES FINANCING AGREEMENT (this ?Amendment?), dated as of October 13, 2021, is entered into by and among the following parties: (i)SYNEOS HEALTH RECEIVABLES LLC, as Borrower; (ii)SYNEOS HEALTH, LLC (f/k/a INC RESEARCH, LLC), as initial Servicer; (iii)REGIONS BANK (?Regions?
November 3, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2021 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission Fi
November 3, 2021	EX-10.2	Sixth Amendment to the Purchase and Sale Agreement, dated as of October 13, 2021, among each of the entities listed on the signature pages hereto as an Originator, Syneos Health, LLC, as servicer, and Syneos Health Receivables LLC. Exhibit 10.2 EXECUTION VERSION SIXTH AMENDMENT TO THE PURCHASE AND SALE AGREEMENT THIS SIXTH AMENDMENT TO THE PURCHASE AND SALE AGREEMENT (this ?Amendment?), dated as of October 13, 2021, is entered into among each of the entities listed on the signature pages hereto as an Originator (each an ?Originator?, and collectively, the ?Originators?), and SYNEOS HEALTH, LLC (f/k/a INC RESEARCH, LLC) (?Syn
November 3, 2021	EX-99.1	Syneos Health Reports Third Quarter 2021 Results Exhibit 99.1 FOR IMMEDIATE RELEASE Syneos Health Reports Third Quarter 2021 Results Highlights ? Third quarter revenue of $1,348.2 million increased 22.7% year-over-year. ? Clinical Solutions net new business awards of $1,353.8 million for the third quarter, representing year-over-year growth of 35.0% and a book-to-bill ratio of 1.30x, and $5,322.2 million for the trailing twelve months, represent
August 9, 2021	EX-4.1	Second Supplemental Indenture, dated as of May 25, 2021, among the Company, the subsidiary guarantors named on the signature pages thereto, the other guarantors, and Wells Fargo Bank, National Association, as trustee. Exhibit 4.1 SECOND SUPPLEMENTAL INDENTURE Second Supplemental Indenture (this ?Supplemental Indenture?), dated as of May 25, 2021, among each undersigned Subsidiary (the ?Guaranteeing Subsidiaries?), each a subsidiary of Syneos Health, Inc. (or its permitted successor), a Delaware corporation (the ?Company?), the Company, the other Guarantors (as defined in the Indenture referred to herein) and We
August 9, 2021	EX-99.1	Syneos Health Reports Second Quarter 2021 Results Exhibit 99.1 FOR IMMEDIATE RELEASE Syneos Health Reports Second Quarter 2021 Results Highlights ? Second quarter revenue of $1,282.6 million, increased 6.1% sequentially and 26.6% year-over-year. ? Clinical Solutions net new business awards of $1,436.2 million for the second quarter, representing year-over-year growth of 21.2% and a book-to-bill ratio of 1.45x, and $4,971.5 million for the trailin
August 9, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36730 SYNEOS H
August 9, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission File
August 9, 2021	EX-10.1	Form of Global Restricted Stock Unit Award Agreement for Directors under Syneos Health, Inc. 2018 Equity Incentive Plan. Exhibit 10.1 SYNEOS HEALTH, INC. 2018 Equity Incentive Plan Global Restricted Stock Unit Award Agreement for Directors This Global Restricted Stock Unit Award Agreement for Directors (the ?Agreement?) is made by and between Syneos Health, Inc., a Delaware corporation (the ?Company?), and [INSERT NAME] (the ?Participant?), effective as of [INSERT DATE OF GRANT] (the ?Date of Grant?). RECITALS WHERE
July 1, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2021 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission File
July 1, 2021	EX-10.1	Amendment No. 5 to the Credit Agreement, dated as of June 30, 2021, among the Company, the other borrowers party thereto, the lenders party thereto, JPMorgan Chase Bank N.A., as Administrative Agent, and each of the other parties thereto. Exhibit 10.1 Execution Version AMENDMENT NO. 5 AMENDMENT NO. 5, dated as of June 30, 2021 (together with all exhibits and schedules hereto, this ?Amendment No. 5? or this ?Agreement?), among SYNEOS HEALTH, INC. (f/k/a INC Research Holdings, Inc.), a Delaware corporation (the ?Administrative Borrower?), the other Borrowers identified on the signature pages hereto (together with the Administrative B
June 16, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2021 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission File
June 9, 2021	EX-99.7	Joint Filing Agreement Exhibit 99.7 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Class A common stock, par value $0.01 per share, of Syneos Health, Inc., a Delaware corporation, and further agree
June 9, 2021	SC 13G	SYNH / Syneos Health Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Syneos Health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 87166B102 (CUSIP Number) May 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat
June 9, 2021	SC 13D/A	SYNH / Syneos Health Inc / ADVENT INTERNATIONAL CORP/MA - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Amendment No. 5 Under the Securities Exchange Act of 1934 SYNEOS HEALTH, INC. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 45329R109 (CUSIP Number) Michael Ristaino, Vice President of Finance - Fund Administration c/o Advent International Corporation Prudential To
June 9, 2021	SC 13D/A	SYNH / Syneos Health Inc / THOMAS H. LEE ADVISORS, LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Amendment No. 7* SYNEOS HEALTH, INC. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 45329R109 (CUSIP Number) Michael J. Aiello, Esq. Sachin Kohli , Esq. Weil, Gotshal & Manges LLP 767 Fifth Avenue New York, NY 10153 (212) 31
June 9, 2021	EX-99.19	JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) Exhibit 99.19 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of the Schedule 13D to which this Agreement is an exhibit (and any further amendment filed by them) with respect to the shares of Class A Common Stock of Syneos Health, I
June 4, 2021	EX-10.1	Share Repurchase Agreement, dated June 1, 2021, by and among Syneos Health, Inc. and certain selling stockholders named therein. Exhibit 10.1 Execution Version STOCK REPURCHASE AGREEMENT THIS STOCK REPURCHASE AGREEMENT (this ?Agreement?) is entered into as of June 1, 2021 by and between Syneos Health, Inc., a Delaware corporation (the ?Company?), Thomas H. Lee Equity Fund VII, L.P., Thomas H. Lee Parallel Fund VII, L.P., THL Executive Fund VII, L.P., THL Fund VII Coinvestment Partners, L.P., THL Equity Fund VII Investors (i
June 4, 2021	424B7	CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered Maximum offering price per share Maximum aggregate offering price Amount of registration fee Class A common stock, $0.01 par value per share 10 Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-228559 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered Maximum offering price per share Maximum aggregate offering price Amount of registration fee Class A common stock, $0.01 par value per share 10,851,676 $81.20 $881,156,091.20 $96,134.13(1) (1) The registration fee
June 4, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission File N
June 4, 2021	EX-1.1	Underwriting Agreement, dated June 2, 2021, by and among Syneos Health, Inc., the selling stockholders named therein and BofA Securities, Inc. Exhibit 1.1 Execution Version Syneos Health, Inc. Class A Common Stock Underwriting Agreement June 2, 2021 BofA Securities, Inc. One Bryant Park New York, NY 10036 Ladies and Gentlemen: The stockholders named in Schedule II hereto (the ?Selling Stockholders?) of Syneos Health, Inc., a Delaware corporation (the ?Company?), propose, subject to the terms and conditions stated herein, to sell to BofA
June 3, 2021	FWP	Syneos Health Announces Secondary Offering of Common Stock Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No.
May 14, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission File N
May 11, 2021	EX-99.16	JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) Exhibit 99.16 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of the Schedule 13D to which this Agreement is an exhibit (and any further amendment filed by them) with respect to the shares of Class A Common Stock of Syneos Health, I
May 11, 2021	SC 13D/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Amendment No. 6* SYNEOS HEALTH, INC. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 45329R109 (CUSIP Number) Michael J. Aiello, Esq. Sachin Kohli , Esq. Weil, Gotshal & Manges LLP 767 Fifth Avenue New York, NY 10153 (212) 31
May 10, 2021	SC 13D/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Amendment No. 4 Under the Securities Exchange Act of 1934 SYNEOS HEALTH, INC. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Sec UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Amendment No. 4 Under the Securities Exchange Act of 1934 SYNEOS HEALTH, INC. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 45329R109 (CUSIP Number) Michael Ristaino, Vice President of Finance - Fund Administration c/o Advent International Corporation Prudential To
May 10, 2021	EX-99.7	Joint Filing Agreement Exhibit 99.7 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Class A common stock, par value $0.01 per share, of Syneos Health, Inc., a Delaware corporation, and further agree
May 5, 2021	EX-10.1	Share Repurchase Agreement, dated April 30, 2021, by and among Syneos Health, Inc. and certain selling stockholders named therein. Exhibit 10.1 STOCK REPURCHASE AGREEMENT THIS STOCK REPURCHASE AGREEMENT (this ?Agreement?) is entered into as of April 30, 2021 by and between Syneos Health, Inc., a Delaware corporation (the ?Company?), Thomas H. Lee Equity Fund VII, L.P., Thomas H. Lee Parallel Fund VII, L.P., THL Executive Fund VII, L.P., THL Fund VII Coinvestment Partners, L.P., THL Equity Fund VII Investors (inVentiv), L.P.,
May 5, 2021	EX-1.1	Underwriting Agreement, dated May 3, 2021, by and among Syneos Health, Inc., the selling stockholders named therein and BofA Securities, Inc.. Exhibit 1.1 Syneos Health, Inc. Class A Common Stock Underwriting Agreement May 3, 2021 BofA Securities, Inc. One Bryant Park New York, NY 10036 Ladies and Gentlemen: The stockholders named in Schedule II hereto (the ?Selling Stockholders?) of Syneos Health, Inc., a Delaware corporation (the ?Company?), propose, subject to the terms and conditions stated herein, to sell to BofA Securities, Inc. (?
May 5, 2021	424B7	CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered Maximum offering price per share Maximum aggregate offering price Amount of registration fee Class A common stock, $0.01 par value per share 8, Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-228559 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered Maximum offering price per share Maximum aggregate offering price Amount of registration fee Class A common stock, $0.01 par value per share 8,050,000(1) $81.04 $652,372,000.00 $71,173.79(2) (1) Includes 1,050,000
May 5, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2021 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission File
May 4, 2021	FWP	Syneos Health Announces Secondary Offering of Common Stock Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No.
April 29, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36730 SYNEOS
April 29, 2021	EX-99.1	Syneos Health Reports First Quarter 2021 Results Exhibit 99.1 FOR IMMEDIATE RELEASE Syneos Health Reports First Quarter 2021 Results Highlights ? Revenue of $1,208.7 million for the three months ended March 31, 2021, representing a sequential increase of 6.0% compared to the three months ended December 31, 2020, and a year-over-year increase of 3.9% compared to the three months ended March 31, 2020. ? Net new business awards of $1,548.8 million
April 29, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2021 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission File
March 31, 2021	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement.
March 31, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement.
March 8, 2021	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2021 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission
March 5, 2021	SC 13D/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Amendment No. 3 Under the Securities Exchange Act of 1934 SYNEOS HEALTH, INC. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Sec SC 13D/A 1 brhc10021382sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Amendment No. 3 Under the Securities Exchange Act of 1934 SYNEOS HEALTH, INC. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 45329R109 (CUSIP Number) Michael Ristaino, Vice President of Finance - Fund Administration c/o Adv
March 5, 2021	SC 13D/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SC 13D/A 1 brhc10021378sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Amendment No. 5* SYNEOS HEALTH, INC. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 45329R109 (CUSIP Number) Michael J. Aiello, Esq. Sachin Kohli , Esq. Weil, Gotshal & Manges LLP 7
March 5, 2021	EX-99.7	Joint Filing Agreement Exhibit 99.7 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Class A common stock, par value $0.01 per share, of Syneos Health, Inc., a Delaware corporation, and further agree
March 5, 2021	EX-99.13	JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) Exhibit 99.13 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of the Schedule 13D to which this Agreement is an exhibit (and any further amendment filed by them) with respect to the shares of Class A Common Stock of Syneos Health, I
March 3, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2021 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission F
March 3, 2021	EX-10.1	Share Repurchase Agreement, dated February 26, 2021, by and among Syneos Health, Inc. and certain selling stockholders named therein. Exhibit 10.1 STOCK REPURCHASE AGREEMENT THIS STOCK REPURCHASE AGREEMENT (this ?Agreement?) is entered into as of February 26, 2021 by and between Syneos Health, Inc., a Delaware corporation (the ?Company?), Thomas H. Lee Equity Fund VII, L.P., Thomas H. Lee Parallel Fund VII, L.P., THL Executive Fund VII, L.P., THL Fund VII Coinvestment Partners, L.P., THL Equity Fund VII Investors (inVentiv), L.P
March 3, 2021	EX-1.1	Underwriting Agreement, dated March 1, 2021, by and among Syneos Health, Inc., the selling stockholders named therein and Goldman Sachs & Co. LLC. EXHIBIT 1.1 Syneos Health, Inc. Class A Common Stock Underwriting Agreement March 1, 2021 Goldman Sachs & Co. LLC 200 West Street New York, NY 10282 Ladies and Gentlemen: The stockholders named in Schedule II hereto (the ?Selling Stockholders?) of Syneos Health, Inc., a Delaware corporation (the ?Company?), propose, subject to the terms and conditions stated herein, to sell to Goldman Sachs & Co.
March 3, 2021	424B7	CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered Maximum offering price per share Maximum aggregate offering price Amount of registration fee Class A common stock, $0.01 par value per share 8, Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-228559 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered Maximum offering price per share Maximum aggregate offering price Amount of registration fee Class A common stock, $0.01 par value per share 8,050,000(1) $74.95 $603,347,500.00 $65,825.22(2) (1) Includes 1,050,000
March 1, 2021	FWP	Syneos Health Announces Secondary Offering of Common Stock Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No.
February 18, 2021	EX-21.1	List of Subsidiaries of the Registrant. Exhibit 21.1 List of Subsidiaries of Syneos Health, Inc. Entity Name Jurisdiction Addison Whitney LLC North Carolina Allidura Communications LLC Delaware BioSector 2 LLC New York Cadent Medical Communications, LLC Ohio Chamberlain Communications Group LLC Delaware Chandler Chicco Agency, L.L.C. New York Cu-Tech, L.L.C. New Jersey Gerbig Snell/Weisheimer Advertising, LLC Ohio Haas & Health Partner
February 18, 2021	EX-10.16	First Amendment to the Purchase and Sale Agreement, dated as of January 2, 2019, among various entities listed on Schedule I thereto, as originators, and Syneos Health, LLC, as servicer, and Syneos Health Receivables LLC as buyer. Exhibit 10.16.2 EXECUTION VERSION FIRST AMENDMENT TO THE PURCHASE AND SALE AGREEMENT THIS FIRST AMENDMENT TO THE PURCHASE AND SALE AGREEMENT (this ?Amendment?), dated as of January 2, 2019, is entered into among the VARIOUS ENTITIES LISTED ON SCHEDULE I HERETO, as originators (each, an ?Originator?; and collectively, the ?Originators?), and SYNEOS HEALTH, LLC (f/k/a INC RESEARCH, LLC), as servicer
February 18, 2021	EX-10.17	Tenth Amendment to the Receivables Financing Agreement, dated as of January 22, 2021, by and among Syneos Health Receivables LLC, as borrower, Syneos Health, LLC, as initial services, Regions Bank, as a lender, and PNC Bank, National Association, as administrative agent and as a lender. Exhibit 10.17.11 EXECUTION VERSION TENTH AMENDMENT TO THE RECEIVABLES FINANCING AGREEMENT This TENTH AMENDMENT TO THE RECEIVABLES FINANCING AGREEMENT (this ?Amendment?), dated as of January 28, 2021, is entered into by and among the following parties: (i) SYNEOS HEALTH RECEIVABLES LLC, as Borrower; (ii) SYNEOS HEALTH, LLC (f/k/a INC RESEARCH, LLC), as initial Servicer; (iii) REGIONS BANK (?Regions
February 18, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2021 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission F
February 18, 2021	EX-10.16	Fifth Amendment to the Purchase and Sale Agreement, dated as of January 22, 2021, among each of the entities listed on the signature pages hereto as an Originator, Syneos Health, LLC, as services, and Syneos Health Receivables LLC. Exhibit 10.16.5 EXECUTION VERSION FIFTH AMENDMENT TO THE PURCHASE AND SALE AGREEMENT THIS FIFTH AMENDMENT TO THE PURCHASE AND SALE AGREEMENT (this ?Amendment?), dated as of January 28, 2021, is entered into among each of the entities listed on the signature pages hereto as an Originator (each an ?Originator?, and collectively, the ?Originators?), and SYNEOS HEALTH, LLC (f/k/a INC RESEARCH, LLC) (?
February 18, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36730 SYNEOS HEALTH,
February 18, 2021	EX-99.1	Syneos Health Reports Fourth Quarter and Full Year 2020 Results Exhibit 99.1 FOR IMMEDIATE RELEASE Syneos Health Reports Fourth Quarter and Full Year 2020 Results Highlights • GAAP revenue of $1,140.0 million for the three months ended December 31, 2020, representing a sequential increase of 3.7% compared to the three months ended September 30, 2020. • Net new business awards of $1,764.1 million and $5,863.1 million for the three and twelve months ended Decemb
February 10, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Syneos Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 87166B102 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒
February 1, 2021	CORRESP	- February 1, 2021 Mr. Abe Friedman Ms. Lyn Shenk Division of Corporation Finance Office of Trade & Services United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Syneos Health, Inc. Form 10-K for the Fiscal Year Ended December 31, 2019 Filed February 20, 2020 File No. 001-36730 Dear Mr. Friedman and Ms. Shenk: Syneos Health, Inc. (the ?Company?, ?we?, or ?ou
January 21, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2021 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission Fi
January 21, 2021	EX-10.2	Form of Global Performance Restricted Stock Unit Award Agreement under Syneos Health, Inc. 2018 Equity Incentive Plan (Non-U.S. Participants) Exhibit 10.2 SYNEOS HEALTH, INC. 2018 Equity Incentive Plan Global Performance Restricted Stock Unit Award Agreement This Global Performance Restricted Stock Unit Award Agreement including any special terms and conditions for the Participant’s country set forth in Appendix B, attached hereto (the Global Performance Restricted Stock Unit Agreement, the Appendix B and all other appendices attached h
January 21, 2021	EX-10.1	Form of Global Performance Restricted Stock Unit Award Agreement under Syneos Health, Inc. 2018 Equity Incentive Plan (U.S. Participants) Exhibit 10.1 SYNEOS HEALTH, INC. 2018 Equity Incentive Plan Global Performance Restricted Stock Unit Award Agreement This Global Performance Restricted Stock Unit Award Agreement including any special terms and conditions for the Participant’s country set forth in Appendix B, attached hereto (the Global Performance Restricted Stock Unit Agreement, the Appendix B and all other appendices attached h
January 13, 2021	EX-99.1	Forward-Looking Statements Except for historical information, all of the statements, expectations, and assumptions contained in this presentation are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act o 39th Annual J.P. Morgan Healthcare Conference Alistair Macdonald January 13, 2021 Exhibit 99.1 Forward-Looking Statements Except for historical information, all of the statements, expectations, and assumptions contained in this presentation are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including the expected impact of the COVID-19 p
January 13, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2021 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission Fi
January 6, 2021	CORRESP	- CORRESP 1 filename1.htm January 6, 2021 Mr. Abe Friedman Ms. Lyn Shenk Mr. Nicholas Lamparski Mr. Dietrich King Division of Corporation Finance Office of Trade & Services United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Syneos Health, Inc. Form 10-K for the Fiscal Year Ended December 31, 2019 Filed February 20, 2020 Form 8-K Furnished October 29, 2020
December 23, 2020	8-K	Regulation FD Disclosure - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2020 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission F
December 7, 2020	SC 13D/A	SYNH / Syneos Health, Inc. / ADVENT INTERNATIONAL CORP/MA - SC 13D/A Activist Investment SC 13D/A 1 brhc10017651sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Amendment No. 2 Under the Securities Exchange Act of 1934 SYNEOS HEALTH, INC. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 45329R109 (CUSIP Number) Michael Ristaino, Vice President of Finance - Fund Administration c/o Adv
December 7, 2020	SC 13D/A	SYNH / Syneos Health, Inc. / THOMAS H. LEE ADVISORS, LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Amendment No. 4* SYNEOS HEALTH, INC. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 45329R109 (CUSIP Number) Michael J. Aiello, Esq. Sachin Kohli , Esq. Weil, Gotshal & Manges LLP 767 Fifth Avenue New York, NY 10153 (212) 31
December 7, 2020	EX-99.4	Joint Filing Agreement Exhibit 99.4 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Class A common stock, par value $0.01 per share, of Syneos Health, Inc., a Delaware corporation, and further agree
December 3, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2020 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission Fi
December 3, 2020	EX-1.1	Underwriting Agreement, dated December 1, 2020, by and among Syneos Health, Inc., the selling stockholders named therein and Goldman Sachs & Co. LLC and BofA Securities, Inc. EX-1.1 Exhibit 1.1 Execution Version Syneos Health, Inc. Class A Common Stock Underwriting Agreement December 1, 2020 Goldman Sachs & Co. LLC 200 West Street New York, NY 10282 BofA Securities, Inc. One Bryant Park New York, NY 10036 Ladies and Gentlemen: The stockholders named in Schedule II hereto (the “Selling Stockholders”) of Syneos Health, Inc., a Delaware corporation (the “Company”), propos
December 3, 2020	424B7	CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered Maximum offering price per share Maximum aggregate offering price Amount of registration fee Class A common stock, $0.01 par value per share 6, 424B7 Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-228559 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered Maximum offering price per share Maximum aggregate offering price Amount of registration fee Class A common stock, $0.01 par value per share 6,000,000 $61.90 $371,400,000.00 $40,519.74(1) (1) The registration
December 1, 2020	FWP	Syneos Health Announces Secondary Offering of Common Stock FWP Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No.
November 25, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 24, 2020 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission F
November 25, 2020	EX-4.3	First Supplemental Indenture, dated as of November 24, 2020, between the Company, the subsidiary guarantors named on the signature pages thereto and Wells Fargo Bank, National Association, as trustee EX-4.3 Exhibit 4.3 Execution Version SYNEOS HEALTH, INC. as Issuer EACH OF THE GUARANTORS PARTY HERETO as Guarantors WELLS FARGO BANK, NATIONAL ASSOCIATION as Trustee First Supplemental Indenture Dated as of November 24, 2020 to the Indenture dated as of November 24, 2020 3.625% Senior Notes due 2029 TABLE OF CONTENTS PAGE ARTICLE 1. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Sectio
November 25, 2020	EX-4.1	Indenture, dated as of November 24, 2020, between Syneos Health, Inc. and Wells Fargo Bank, National Association, as trustee EX-4.1 Exhibit 4.1 Execution Version Syneos Health, Inc. INDENTURE Dated as of November 24, 2020 Wells Fargo Bank, National Association as Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 SECTION 1.1. Definitions 1 SECTION 1.2. Concerning the Trust Indenture Act 6 SECTION 1.3. Rules of Construction 6 ARTICLE II THE SECURITIES 7 SECTION 2.1. Issuable in Series 7
November 25, 2020	EX-4.4	Amendment No. 4 to the Credit Agreement dated as of November 24, 2020, by and among the Borrowers, the Lenders from time to time party thereto, and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent for the Lenders EX-4.4 Exhibit 4.4 EXECUTION VERSION AMENDMENT NO. 4 AMENDMENT NO. 4, dated as of November 24, 2020 (together with all exhibits and schedules hereto, this “Amendment No. 4” or this “Agreement”), among SYNEOS HEALTH, INC. (f/k/a INC Research Holdings, Inc.), a Delaware corporation (the “Administrative Borrower”), the other Borrowers identified on the signature pages hereto (together with the Admini
November 25, 2020	EX-99.1	Syneos Health Announces Closing of Offering of $600.0 Million of Senior Notes due 2029 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Syneos Health Announces Closing of Offering of $600.0 Million of Senior Notes due 2029 MORRISVILLE, N.C. – November 24, 2020 — Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization
November 19, 2020	EX-99.1	Syneos Health Announces Upsizing and Pricing of Offering of $600.0 Million of Senior Notes due 2029 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Syneos Health Announces Upsizing and Pricing of Offering of $600.0 Million of Senior Notes due 2029 MORRISVILLE, N.C. – November 18, 2020 — Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial
November 19, 2020	8-K	Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2020 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission F
November 18, 2020	EX-99.1	Syneos Health Announces Senior Notes Offering EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Syneos Health Announces Senior Notes Offering MORRISVILLE, N.C. – November 18, 2020 — Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced it commenced an offeri
November 18, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2020 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission F
November 17, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2020 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission F
October 29, 2020	EX-10.1	Fourth Amendment to the Purchase and Sale Agreement, dated as of September 25, 2020, among each of the entities listed on the signature pages as a New Originator, each of the entities listed on the signature pages as an Existing Originator, and Syneos Health, LLC, as servicer, and Syneos Health Receivables LLC. Exhibit 10.1 EXECUTION VERSION FOURTH AMENDMENT TO THE PURCHASE AND SALE AGREEMENT THIS FOURTH AMENDMENT TO THE PURCHASE AND SALE AGREEMENT (this “Amendment”), dated as of September 25, 2020, is entered into among each of the entities listed on the signature pages hereto as a New Originator (each a “New Originator”, and collectively, the “New Originators”), each of the entities listed on the signa
October 29, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36730 SYN
October 29, 2020	EX-99.1	Syneos Health Reports Third Quarter 2020 Results Exhibit 99.1 FOR IMMEDIATE RELEASE Syneos Health Reports Third Quarter 2020 Results Highlights • Announced agreement to acquire Synteract, a mid-sized, full-service CRO focused on the fast growing emerging biopharma sector. • GAAP revenue of $1,099.0 million for the three months ended September 30, 2020, representing a sequential increase of 8.4% compared to the three months ended June 30, 2020. •
October 29, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2020 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission Fi
October 29, 2020	EX-10.2	Ninth Amendment to the Receivables Financing Agreement, dated as of September 25, 2020, by and among Syneos Health Receivables LLC, as borrower, Syneos Health, LLC, as initial servicer, and PNC Bank, National Association, as administrative agent and as lender. Exhibit 10.2 EXECUTION VERSION NINTH AMENDMENT TO THE RECEIVABLES FINANCING AGREEMENT This NINTH AMENDMENT TO THE RECEIVABLES FINANCING AGREEMENT (this “Amendment”), dated as of September 25, 2020, is entered into by and among the following parties: (i) SYNEOS HEALTH RECEIVABLES LLC, as Borrower; (ii) SYNEOS HEALTH, LLC (f/k/a INC RESEARCH, LLC), as initial Servicer; and (iii) PNC BANK, NATIONAL A
October 29, 2020	EX-10.3	Second Amendment to the Purchase and Sale Agreement, dated as of July 25, 2019, among inVentiv Commercial Services, LLC, each of the entities listed on the signature pages as an Existing Originator, and Syneos Health, LLC, as servicer, and Syneos Health Receivables LLC. Exhibit 10.3 EXECUTION VERSION SECOND AMENDMENT TO THE PURCHASE AND SALE AGREEMENT THIS SECOND AMENDMENT TO THE PURCHASE AND SALE AGREEMENT (this “Amendment”), dated as of July 25, 2019, is entered into among INVENTIV COMMERCIAL SERVICES, LLC (the “New Originator”), each of the entities listed on the signature pages hereto as an Existing Originator (each, an “Existing Originator” and collectively,
October 29, 2020	EX-2.1	Stock Purchase Agreement, dated as of October 26, 2020, by and between SHCR Holdings, LLC and Syneos Health Clinical, Inc. Exhibit 2.1 EXECUTION VERSION STOCK PURCHASE AGREEMENT BY AND BETWEEN SHCR HOLDINGS, LLC AND SYNEOS HEALTH CLINICAL, INC. DATED AS OF OCTOBER 26, 2020 TABLE OF CONTENTS Page Article I CERTAIN DEFINITIONS 1.1 Certain Definitions 1 Article II PURCHASE AND SALE 2.1 Purchase and Sale of the Shares 15 2.2 Consideration 15 2.3 Adjustments to the Net Purchase Price 15 Article III CLOSING 3.1 Closing 19 3
September 22, 2020	EX-99.2	Joint Filer Information Exhibit 99.2 Joint Filer Information Name of Joint Filer: Double Eagle Investor Holdings, L.P. Address of Joint Filer: c/o Advent International Corporation Prudential Tower, 800 Boylston Street, Suite 3300 Boston, MA 02199-8069 Relationship of Joint Filer to Issuer: 10% Owner Issuer Name and Ticker or Trading Symbol: Syneos Health, Inc. [SYNH] Date of Earliest Transaction Required to be Reported (
September 22, 2020	EX-99.2	Joint Filer Information Exhibit 99.2 Joint Filer Information Name of Joint Filer: Double Eagle Investor Holdings, L.P. Address of Joint Filer: c/o Advent International Corporation Prudential Tower, 800 Boylston Street, Suite 3300 Boston, MA 02199-8069 Relationship of Joint Filer to Issuer: 10% Owner Issuer Name and Ticker or Trading Symbol: Syneos Health, Inc. [SYNH] Date of Earliest Transaction Required to be Reported (
September 22, 2020	EX-99.1	Footnotes to Form 4 Exhibit 99.1 Name and Address of Reporting Person: Advent International Corporation Prudential Tower, 800 Boylston Street, Suite 3300 Boston, MA 02199-8069 Issuer Name and Ticker or Trading Symbol: Syneos Health, Inc. [SYNH] Date of Earliest Transaction Required to be Reported: September 17, 2020 (Month/Day/Year) Footnotes to Form 4 (1) Represents shares of Class A Common Stock (“Common Stock”) of
September 22, 2020	EX-99.1	Footnotes to Form 4 Exhibit 99.1 Name and Address of Reporting Person: Advent International Corporation Prudential Tower, 800 Boylston Street, Suite 3300 Boston, MA 02199-8069 Issuer Name and Ticker or Trading Symbol: Syneos Health, Inc. [SYNH] Date of Earliest Transaction Required to be Reported: September 17, 2020 (Month/Day/Year) Footnotes to Form 4 (1) Represents shares of Class A Common Stock (“Common Stock”) of
September 22, 2020	SC 13D/A	SYNH / Syneos Health, Inc. / ADVENT INTERNATIONAL CORP/MA - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Amendment No. 1 Under the Securities Exchange Act of 1934 SYNEOS HEALTH, INC. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 45329R109 (CUSIP Number) Michael Ristaino, Vice President of Finance – Fund Administration c/o Advent International Corporation Prudential To
September 22, 2020	EX-99.4	Joint Filing Agreement Exhibit 99.4 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Class A common stock, par value $0.01 per share, of Syneos Health, Inc., a Delaware corporation, and further agree
September 22, 2020	EX-99.1	Footnotes to Form 4 Exhibit 99.1 Name and Address of Reporting Person: Advent International Corporation Prudential Tower, 800 Boylston Street, Suite 3300 Boston, MA 02199-8069 Issuer Name and Ticker or Trading Symbol: Syneos Health, Inc. [SYNH] Date of Earliest Transaction Required to be Reported: September 17, 2020 (Month/Day/Year) Footnotes to Form 4 (1) Represents shares of Class A Common Stock (“Common Stock”) of
September 22, 2020	EX-99.1	Footnotes to Form 4 Exhibit 99.1 Name and Address of Reporting Person: Advent International Corporation Prudential Tower, 800 Boylston Street, Suite 3300 Boston, MA 02199-8069 Issuer Name and Ticker or Trading Symbol: Syneos Health, Inc. [SYNH] Date of Earliest Transaction Required to be Reported: September 17, 2020 (Month/Day/Year) Footnotes to Form 4 (1) Represents shares of Class A Common Stock (“Common Stock”) of
September 22, 2020	EX-99.2	Joint Filer Information Exhibit 99.2 Joint Filer Information Name of Joint Filer: Double Eagle Investor Holdings, L.P. Address of Joint Filer: c/o Advent International Corporation Prudential Tower, 800 Boylston Street, Suite 3300 Boston, MA 02199-8069 Relationship of Joint Filer to Issuer: 10% Owner Issuer Name and Ticker or Trading Symbol: Syneos Health, Inc. [SYNH] Date of Earliest Transaction Required to be Reported (
September 22, 2020	EX-99.2	Joint Filer Information Exhibit 99.2 Joint Filer Information Name of Joint Filer: Double Eagle Investor Holdings, L.P. Address of Joint Filer: c/o Advent International Corporation Prudential Tower, 800 Boylston Street, Suite 3300 Boston, MA 02199-8069 Relationship of Joint Filer to Issuer: 10% Owner Issuer Name and Ticker or Trading Symbol: Syneos Health, Inc. [SYNH] Date of Earliest Transaction Required to be Reported (
September 22, 2020	EX-99.1	Footnotes to Form 4 Exhibit 99.1 Name and Address of Reporting Person: Advent International Corporation Prudential Tower, 800 Boylston Street, Suite 3300 Boston, MA 02199-8069 Issuer Name and Ticker or Trading Symbol: Syneos Health, Inc. [SYNH] Date of Earliest Transaction Required to be Reported: September 17, 2020 (Month/Day/Year) Footnotes to Form 4 (1) Represents shares of Class A Common Stock (“Common Stock”) of
September 22, 2020	EX-99.1	Footnotes to Form 4 Exhibit 99.1 Name and Address of Reporting Person: Advent International Corporation Prudential Tower, 800 Boylston Street, Suite 3300 Boston, MA 02199-8069 Issuer Name and Ticker or Trading Symbol: Syneos Health, Inc. [SYNH] Date of Earliest Transaction Required to be Reported: September 17, 2020 (Month/Day/Year) Footnotes to Form 4 (1) Represents shares of Class A Common Stock (“Common Stock”) of
September 22, 2020	EX-99.2	Joint Filer Information Exhibit 99.2 Joint Filer Information Name of Joint Filer: Double Eagle Investor Holdings, L.P. Address of Joint Filer: c/o Advent International Corporation Prudential Tower, 800 Boylston Street, Suite 3300 Boston, MA 02199-8069 Relationship of Joint Filer to Issuer: 10% Owner Issuer Name and Ticker or Trading Symbol: Syneos Health, Inc. [SYNH] Date of Earliest Transaction Required to be Reported (
September 22, 2020	EX-99.2	Joint Filer Information Exhibit 99.2 Joint Filer Information Name of Joint Filer: Double Eagle Investor Holdings, L.P. Address of Joint Filer: c/o Advent International Corporation Prudential Tower, 800 Boylston Street, Suite 3300 Boston, MA 02199-8069 Relationship of Joint Filer to Issuer: 10% Owner Issuer Name and Ticker or Trading Symbol: Syneos Health, Inc. [SYNH] Date of Earliest Transaction Required to be Reported (
September 21, 2020	EX-99.15	JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) Exhibit 99.15 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of the Schedule 13D to which this Agreement is an exhibit (and any further amendment filed by them) with respect to the shares of Class A Common Stock of Syneos Health, I
September 21, 2020	SC 13D/A	SYNH / Syneos Health, Inc. / THOMAS H. LEE ADVISORS, LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to SCHEDULE 13D Under the Securities Exchange Act of 1934 SYNEOS HEALTH, INC. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 45329R109 (CUSIP Number) Michael J. Aiello, Esq. Sachin Kohli , Esq. Weil, Gotshal & Manges LLP 767 Fifth Avenue New York, NY 10153 (212)
September 17, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2020 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission
September 17, 2020	EX-1.1	Underwriting Agreement, dated September 15, 2020, by and among Syneos Health, Inc., the selling stockholders named therein and Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC. EX-1.1 EXHIBIT 1.1 Syneos Health, Inc. Class A Common Stock Underwriting Agreement September 15, 2020 Goldman Sachs & Co. LLC 200 West Street New York, NY 10282 Morgan Stanley & Co. LLC 180 Varick Street, 2nd Floor New York, New York 10014 Ladies and Gentlemen: The stockholders named in Schedule II hereto (the “Selling Stockholders”) of Syneos Health, Inc., a Delaware corporation (the “Company”),
September 16, 2020	424B7	CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered Maximum offering price per share Maximum aggregate offering price Amount of registration fee Class A common stock, $0.01 par value per share 7, 424B7 1 d176963d424b7.htm 424B7 Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-228559 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered Maximum offering price per share Maximum aggregate offering price Amount of registration fee Class A common stock, $0.01 par value per share 7,000,000 $59.75 $418,250,000.00 $54,288.
September 15, 2020	FWP	Syneos Health Announces Secondary Offering of Common Stock FWP 1 d159459dfwp.htm FWP Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. 333-228559 September 15, 2020 Syneos Health Announces Secondary Offering of Common Stock MORRISVILLE, N.C. – September 15, 2020 — Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a CRO (Cont
August 6, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36730 SYNEOS H
August 6, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission File
August 6, 2020	EX-10.1	Form of Director Indemnification Agreement Exhibit 10.1 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of - -, 20- between Syneos Health, Inc., a Delaware corporation (the “Company”) and (“Indemnitee”), a member of the Board of Directors of the Company. Capitalized terms not defined elsewhere in this Agreement shall have the meanings ascribed to them in Section 17 herein. WHEREAS, hig
August 6, 2020	EX-99.1	Syneos Health Reports Second Quarter 2020 Results EX-99.1 2 synh-ex9916.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Syneos Health Reports Second Quarter 2020 Results Highlights • GAAP revenue of $1,013.4 million for the three months ended June 30, 2020, representing a decline of 13.1%, 13.3% on an adjusted basis, and 12.8% on a constant currency adjusted basis compared to the same period in 2019. • Net new business awards of $1,360.9 million a
June 3, 2020	EX-99.1	Exhibit 99.1 Jefferies Virtual Healthcare Conference Alistair Macdonald Chief Executive Officer June 3, 2020 Forward-Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements Except for historical information, all of the statement synhjefferies2020presen Exhibit 99.1 Jefferies Virtual Healthcare Conference Alistair Macdonald Chief Executive Officer June 3, 2020 Forward-Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements Except for historical information, all of the statements, expectations, and assumptions contained in this EBITDA, adjusted EBITDA, and adjusted EBITDA margin. We also include in thi
June 3, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2020 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission File N
June 1, 2020	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2020 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission File N
April 30, 2020	EX-10.1	Eighth Amendment to the Receivables Financing Agreement, dated March 18, 2020, among Syneos Health Receivables LLC, as borrower, Syneos Health, LLC as initial servicer, and PNC Bank, National Association, as administrative agent and as lender. Exhibit 10.1 EXECUTION VERSION EIGHTH AMENDMENT TO THE RECEIVABLES FINANCING AGREEMENT This EIGHTH AMENDMENT TO THE RECEIVABLES FINANCING AGREEMENT (this “Amendment”), dated as of March 18, 2020, is entered into by and among the following parties: (i) SYNEOS HEALTH RECEIVABLES LLC, as Borrower; (ii) SYNEOS HEALTH, LLC (f/k/a INC RESEARCH, LLC), as initial Servicer; and (iii) PNC BANK, NATIONAL ASS
April 30, 2020	EX-10.8	Letter Agreement between Syneos Health UK Limited and Alistair Macdonald, dated May 3, 2019. Exhibit 10.8 INC Research UK Limited \| Farnborough Business Park, 1 Pinehurst Road, Farnborough, Hampshire, GU14 7BF, United Kingdom Registered in England and Wales No.: 04428083 T: +44 (0)1276 713000 3rd May 2019 Mr. A. MacDonald Via Email Dear Alistair, Following our recent communications, we are writing to confirm the following details of a change to contract due to the recent strategy to strea
April 30, 2020	EX-10.2	Amendment No. 3 to the Credit Agreement, dated as of April 7, 2020, by and between Syneos Health, Inc. as Administrative Borrower and JPMorgan Chase Bank, N.A., as Administrative Agent. Exhibit 10.2 Execution Version AMENDMENT NO. 3 AMENDMENT NO. 3, dated as of April 7, 2020 (this “Amendment”) by and between SYNEOS HEALTH, INC., a Delaware corporation (the “Administrative Borrower”) and JPMORGAN CHASE BANK, N.A., as Administrative Agent for the Lenders (in such capacity, the “Administrative Agent”), relating to that certain Credit Agreement, dated as of August 1, 2017 (as amended
April 30, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36730 SYNEOS
April 30, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2020 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission File
April 30, 2020	EX-99.1	Syneos Health Reports First Quarter 2020 Results Exhibit 99.1 FOR IMMEDIATE RELEASE Syneos Health Reports First Quarter 2020 Results Highlights •GAAP revenue of $1,163.4 million for the three months ended March 31, 2020, representing growth of 4.0%, 3.8% on an adjusted basis, and 4.4% on a constant currency adjusted basis compared to the same period in 2019. •Net new business awards of $1,531.6 million and $5,724.7 million for the three and twel
April 22, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2020 SYNEOS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36730 27-3403111 (State or other jurisdiction of incorporation) (Commission File
April 22, 2020	EX-10.1	Letter Agreement between INC Research Holding Limited and Alistair Macdonald, dated April 18, 2020. Exhibit 10.1 April 18, 2020 Alistair Macdonald [personal address] Re: Waiver of Compensation Dear Alistair: This letter serves to memorialize your agreement to reduce your annual base salary from $1,060,000 (the “Original Base Salary”) to $742,000 from May 1, 2020 through September 30, 2020 (the “Waiver Period”), subject to extension of the Waiver Period by mutual written agreement of you and INC
April 22, 2020	EX-10.3	Letter Agreement between Syneos Health, Inc. and Michelle Keefe, dated April 18, 2020. Exhibit 10.3 April 18, 2020 Michelle Keefe [personal address] Re: Waiver of Compensation Dear Michelle: This letter serves to memorialize your agreement to reduce your annual base salary from $567,000 (the “Original Base Salary”) to $460,000 from May 1, 2020 through September 30, 2020 (the “Waiver Period”), subject to extension of the Waiver Period by mutual written agreement of you and Syneos Hea
April 22, 2020	EX-10.5	Letter Agreement between Syneos Health, Inc. and Jonathan Olefson, dated April 18, 2020. Exhibit 10.5 April 18, 2020 Jonathan Olefson [personal address] Re: Waiver of Compensation Dear Jon: This letter serves to memorialize your agreement to reduce your annual base salary from $465,000 (the “Original Base Salary”) to $399,000 from May 1, 2020 through September 30, 2020 (the “Waiver Period”), subject to extension of the Waiver Period by mutual written agreement of you and Syneos Health
April 22, 2020	EX-10.4	Letter Agreement between Syneos Health, Inc. and Paul Colvin, dated April 18, 2020. Exhibit 10.4 April 18, 2020 Paul Colvin [personal address] Re: Waiver of Compensation Dear Paul: This letter serves to memorialize your agreement to reduce your annual base salary from $567,000 (the “Original Base Salary”) to $460,000 from May 1, 2020 through September 30, 2020 (the “Waiver Period”), subject to extension of the Waiver Period by mutual written agreement of you and Syneos Health, In
April 22, 2020	EX-10.2	Letter Agreement between Syneos Health, Inc. and Jason Meggs, dated April 18, 2020. Exhibit 10.2 April 18, 2020 Jason Meggs [personal address] Re: Waiver of Compensation Dear Jason: This letter serves to memorialize your agreement to reduce your annual base salary from $600,000 (the “Original Base Salary”) to $480,000 from May 1, 2020 through September 30, 2020 (the “Waiver Period”), subject to extension of the Waiver Period by mutual written agreement of you and Syneos Health, I
April 16, 2020	DEF 14A	Schedule 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement.

SYNH / Syneos Health Inc - Class A - SEC Filings, Annual Report, Proxy Statement

Basic Stats

SEC Filings

SEC Filings (Chronological Order)